STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Elanco Animal Health Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Elanco Animal Health (ELAN) furnished a Current Report announcing results for the fiscal quarter ended September 30, 2025, along with guidance for the full year and fourth quarter of 2025. The details are provided in a press release attached as Exhibit 99.1, dated November 5, 2025.

The Item 2.02 information, including Exhibit 99.1, was furnished and is not deemed filed under the Exchange Act.

Positive
  • None.
Negative
  • None.
FALSE000173910400017391042025-11-052025-11-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
Form 8-K
_______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

Elanco Animal Health Incorporated
(Exact name of Registrant as specified in its charter)
INDIANA
001-38661 82-5497352
(State or other jurisdiction of(Commission File (I.R.S. Employer
incorporation)Number) Identification No.)
450 ELANCO CIRCLE
 46221
INDIANAPOLIS, INDIANA
 (Zip Code)
(Address of principal executive offices) 
Registrant’s telephone number, including area code: (877352-6261

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, no par valueELANNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02    Results of Operations or Financial Condition.
Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated November 5, 2025, announcing the results of operations for the fiscal quarter ended September 30, 2025, and guidance for the full year and fourth quarter of 2025, for Elanco Animal Health Incorporated.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01    Financial Statements and Exhibits.
(d) Exhibits

Exhibit NumberDescription
99.1
Press Release issued by Elanco Animal Health Incorporated dated November 5, 2025
104.1Cover Page Interactive Data File (embedded within the Inline XBRL document)


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ELANCO ANIMAL HEALTH INCORPORATED
Date:November 5, 2025/s/ Robert M. VanHimbergen
Robert M. VanHimbergen
Executive Vice President and Chief Financial Officer

FAQ

What did Elanco (ELAN) report in this 8-K?

It furnished a press release announcing results for the quarter ended September 30, 2025, and guidance for the full year and fourth quarter of 2025.

Which exhibit contains the earnings press release for ELAN?

The press release is attached as Exhibit 99.1.

Is the information in this 8-K considered filed or furnished?

The Item 2.02 information, including Exhibit 99.1, was furnished and is not deemed filed under the Exchange Act.

What period do the reported results cover for ELAN?

The fiscal quarter ended September 30, 2025.

Does the filing include guidance for ELAN?

Yes. It includes guidance for the full year 2025 and the fourth quarter of 2025.

What is Elanco’s trading symbol and exchange?

Elanco trades as ELAN on the New York Stock Exchange.
Elanco Animal Health

NYSE:ELAN

ELAN Rankings

ELAN Latest News

ELAN Latest SEC Filings

ELAN Stock Data

11.35B
491.32M
1.03%
109.82%
5.2%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
GREENFIELD